BACKGROUND: Two promising recombinant meningococcal protein vaccines are in development. One contains factor H-binding protein (fHBP) variants (v.) 1 and 2, whereas the other contains v.1 and 4 other antigens discovered by genome mining (5 component [5C]). Antibodies against fHBP are bactericidal against strains within a variant group. There are limited data on the prevalence of strains expressing different fHBP variants in the United States. METHODS: A total of 143 group B isolates from patients hospitalized in the United States were tested for fHBP variant by quantitative polymerase chain reaction, for reactivity with 6 anti-fHBP monoclonal antibodies (MAb) by dot immunoblotting, and for susceptibility to bactericidal activity of mouse antisera. RESULTS: fHBP v.1 isolates predominated in California (83%), whereas isolates expressing v.1 (53%) or v.2 (42%) were common in 9 other states. Isolates representative of 5 anti-fHBP MAb-binding phenotypes (70% of isolates) were highly susceptible to anti-fHBP v.1 or v.2 bactericidal activity, whereas 3 phenotypes were approximately 50% susceptible. Collectively, antibodies against the fHBP v.1 and v.2 vaccine and the 5C vaccine killed 76% and 83% of isolates, respectively. CONCLUSIONS: Susceptibility to bactericidal activity can be predicted, in part, on the basis of fHBP phenotypes. Both vaccines have the potential to prevent most group B disease in the United States.
BACKGROUND: Two promising recombinant meningococcal protein vaccines are in development. One contains factor H-binding protein (fHBP) variants (v.) 1 and 2, whereas the other contains v.1 and 4 other antigens discovered by genome mining (5 component [5C]). Antibodies against fHBP are bactericidal against strains within a variant group. There are limited data on the prevalence of strains expressing different fHBP variants in the United States. METHODS: A total of 143 group B isolates from patients hospitalized in the United States were tested for fHBP variant by quantitative polymerase chain reaction, for reactivity with 6 anti-fHBP monoclonal antibodies (MAb) by dot immunoblotting, and for susceptibility to bactericidal activity of mouse antisera. RESULTS: fHBP v.1 isolates predominated in California (83%), whereas isolates expressing v.1 (53%) or v.2 (42%) were common in 9 other states. Isolates representative of 5 anti-fHBP MAb-binding phenotypes (70% of isolates) were highly susceptible to anti-fHBP v.1 or v.2 bactericidal activity, whereas 3 phenotypes were approximately 50% susceptible. Collectively, antibodies against the fHBP v.1 and v.2 vaccine and the 5C vaccine killed 76% and 83% of isolates, respectively. CONCLUSIONS: Susceptibility to bactericidal activity can be predicted, in part, on the basis of fHBP phenotypes. Both vaccines have the potential to prevent most group B disease in the United States.
Authors: S L Morley; M J Cole; C A Ison; M A Camaraza; F Sotolongo; N Anwar; I Cuevas; M Carbonero; H C Campa; G Sierra; M Levin Journal: Pediatr Infect Dis J Date: 2001-11 Impact factor: 2.129
Authors: M Pizza; V Scarlato; V Masignani; M M Giuliani; B Aricò; M Comanducci; G T Jennings; L Baldi; E Bartolini; B Capecchi; C L Galeotti; E Luzzi; R Manetti; E Marchetti; M Mora; S Nuti; G Ratti; L Santini; S Savino; M Scarselli; E Storni; P Zuo; M Broeker; E Hundt; B Knapp; E Blair; T Mason; H Tettelin; D W Hood; A C Jeffries; N J Saunders; D M Granoff; J C Venter; E R Moxon; G Grandi; R Rappuoli Journal: Science Date: 2000-03-10 Impact factor: 47.728
Authors: James D Campbell; Robert Edelman; James C King; Thomas Papa; Robert Ryall; Margaret B Rennels Journal: J Infect Dis Date: 2002-11-14 Impact factor: 5.226
Authors: Peter T Beernink; Jo Anne Welsch; Michal Bar-Lev; Oliver Koeberling; Maurizio Comanducci; Dan M Granoff Journal: Infect Immun Date: 2008-06-30 Impact factor: 3.441